NEW YORK – Nuevocor earlier this week announced it raised $45 million in a Series B funding round, which will support a Phase I/II trial of its gene therapy candidate, NVC-001, in a form of dilated cardiomyopathy (DCM) due to LMNA gene mutations.
The financing round was co-led by Kurma Partners and Angelini Ventures. It also included participation from existing investors EDBI, ClavystBio, and Boehringer Ingelheim Venture Fund, as well as from Highlight Capital and SEEDS Capital.
The Singapore-based firm plans to use the proceeds to support a first-in-human trial of NVC-001 in LMNA-related DCM in the US and Europe and open an office in Paris.
LMNA DCM, an aggressive form of dilated cardiomyopathy, is an autosomal dominant disease characterized by gain-of-function variants in the LMNA gene, which encodes the lamin A/C protein. Patients with LMNA DCM can progress rapidly, experience ventricular arrhythmias, and are at risk of sudden cardiac death.
NVC-001, an AAV-based gene therapy developed using Nuevocor's PrOSIA mechanobiology platform, is designed to overexpress a transgene that suppresses the pathology of LMNA mutations, restoring nuclear envelope integrity and treating the disease. The firm plans to initiate the first-in-human trial in early 2026, alongside a natural history study.
"We are excited by Nuevocor's novel approach to treating genetic-dilated cardiomyopathy by targeting mechanobiological pathways rather than simply replacing genes," Angelini Ventures Managing Director Elia Stupka said in a statement. "This one-time therapy has the potential to transform patient outcomes and ease healthcare burdens."
Following the funding round, Stupka and Kurma Partners' Amanda Gett-Chaperot will join Nuevocor's board of directors.